Antares Pharma, Inc. (ATRS)

2.75
0.03 1.10
NASDAQ
Prev Close 2.72
Open 2.74
Day Low/High 2.65 / 2.76
52 Wk Low/High 1.99 / 3.93
Volume 775.29K
Exchange NASDAQ
Shares Outstanding 160.53B
Market Cap 436.65M
Div & Yield N.A. (N.A)
Antares Pharma To Participate In The 2013 RBC Capital Markets’ Healthcare Conference

Antares Pharma To Participate In The 2013 RBC Capital Markets’ Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

'Mad Money' Lightning Round: Cisco Is Good

'Mad Money' Lightning Round: Cisco Is Good

Cramer also likes Total but he's not crazy about Antares Pharma, Chesapeake Energy or EMC.

Cramer's 'Mad Money' Recap: Lose the Gloom and Doom

Cramer's 'Mad Money' Recap: Lose the Gloom and Doom

Investors need to ignore the bad news because the time to invest is now, Cramer said.

Antares Pharma Announces Submission Of New Drug Application For OTREXUP™

Antares Pharma Announces Submission Of New Drug Application For OTREXUP™

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the submission of a New Drug Application (NDA) to the U.

Antares Pharma To Present At The Oppenheimer 23rd Annual Healthcare Conference

Antares Pharma To Present At The Oppenheimer 23rd Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

'Mad Money' Lightning Round: Take the Money and Run From AEO

'Mad Money' Lightning Round: Take the Money and Run From AEO

Cramer also says to avoid Antares Pharma and Frontier Communications but would go with Apple and Linn Energy.

Cramer's 'Mad Money' Recap: Reasons to Worry

Cramer's 'Mad Money' Recap: Reasons to Worry

The optimists think going over the 'fiscal cliff' is no big deal. Cramer thinks they're dead wrong.

Antares Pharma Announces Positive Results From Final MTX Medi-Jet™ Clinical Study

Antares Pharma Announces Positive Results From Final MTX Medi-Jet™ Clinical Study

Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from an open-label, randomized, crossover study comparing the systemic availability of MTX Medi-Jet to oral methotrexate (MTX) in adult patients with...

Antares Pharma To Present At The Jefferies 2012 Global Healthcare Conference

Antares Pharma To Present At The Jefferies 2012 Global Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma Reports Third Quarter 2012 Financial And Operating Results

Antares Pharma Reports Third Quarter 2012 Financial And Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported financial and operating results for the third quarter ended September 30, 2012.

Antares Pharma To Host Third Quarter 2012 Earnings Call

Antares Pharma To Host Third Quarter 2012 Earnings Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2012 financial results before the market opens on Wednesday, November 7, 2012, and host a conference call shortly thereafter at 8:30...

Antares Pharma Announces Closing Of Public Offering Of Common Stock

Antares Pharma Announces Closing Of Public Offering Of Common Stock

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the closing of its previously announced firm commitment underwritten public offering of 12,500,000 shares of the Company’s common stock at a purchase price of ...

Antares Pharma Announces Pricing Of Public Offering Of Common Stock

Antares Pharma Announces Pricing Of Public Offering Of Common Stock

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has priced a firm commitment underwritten public offering of 12,500,000 shares of the Company’s common stock at a purchase price to the public of $4.

Antares Pharma Announces Proposed Public Offering Of Common Stock

Antares Pharma Announces Proposed Public Offering Of Common Stock

Antares Pharma, Inc. (NASDAQ: ATRS) today announced a public offering of shares of its common stock.

Antares Pharma Receives Development Milestone Payment

Antares Pharma Receives Development Milestone Payment

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that its partner Pfizer Inc.

Antares Pharma Announces Successful Results From VIBEX MTX Actual Human Use Study

Antares Pharma Announces Successful Results From VIBEX MTX Actual Human Use Study

Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX).

5 Stocks Under $5 Moving Higher

5 Stocks Under $5 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Antares Pharma To Present At The Stifel Nicolaus 2012 Healthcare Conference

Antares Pharma To Present At The Stifel Nicolaus 2012 Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma Inc. Stock Downgraded (ATRS)

Antares Pharma Inc. Stock Downgraded (ATRS)

Antares Pharma (Nasdaq:ATRS) has been downgraded by TheStreet Ratings from from a hold to sell.

Antares Pharma Reports Second Quarter 2012 Financial And Operating Results

Antares Pharma Reports Second Quarter 2012 Financial And Operating Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported financial and operating results for the second quarter ended June 30, 2012.

Antares Pharma To Host Second Quarter 2012 Earnings Call

Antares Pharma To Host Second Quarter 2012 Earnings Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2012 financial results before the market opens on Wednesday, August 8, 2012, and host a conference call shortly thereafter at 8:30...

7 Stocks Under $10 With Relative Strength

7 Stocks Under $10 With Relative Strength

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Antares Pharma Appoints Jonathan S. Jaffe MD Vice President Of Clinical Development

Antares Pharma Appoints Jonathan S. Jaffe MD Vice President Of Clinical Development

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Jonathan S.

Antares Stock Hits New 52-Week High (ATRS)

Antares Stock Hits New 52-Week High (ATRS)

Antares Pharma (Nasdaq:ATRS) hit a new 52-week high Tuesday as it is currently trading at $3.84, above its previous 52-week high of $3.75 with 325,626 shares traded as of 9:40 a.m. ET. Average volume has been one million shares over the past 30 days.

Antares Pharma Announces Positive Results From VIBEX MTX Usability Study

Antares Pharma Announces Positive Results From VIBEX MTX Usability Study

Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a human factors usability study for VIBEX Methotrexate (MTX), a proprietary auto injector product designed to self-administer a rapid ...

Should I Do It? Symantec Bar Set Low

The market is pricing in a weak 2007, but near-term downside is limited and shares should lift.

Stocks Close Little Changed

The major averages end below their session highs.

Symantec Can't Break Spending Habit

Investors question whether it's time for another large buy.

Monday's Tech Winners & Losers

Altiris takes off, while Radware slumps.

Symantec Buying Altiris

The deal offers a 22% premium.

TheStreet Quant Rating: C (Hold)